Perrigo Company plc Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $270.30 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2017-11-09
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2017-09-30 was $61.40M, a 56.63% increase year-over-year.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2017-07-01 was $155.10M.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2017-04-01 was $53.80M, a 64.74% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2016-12-31 was -$149.80M.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2016 was -$64.50M.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2015 was -$51.00M, a 203.45% decline from fiscal 2014.
- Perrigo Company plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2014 was $49.30M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month as first filed | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | $61.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $216.50M derived: sum of 2 quarters · filed 2017-11-09 | $270.30M 10-Q · filed 2017-11-09 | $120.50M derived: sum of 4 quarters · filed 2017-11-09 | ||||
| 2017-07-01 | $155.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $208.90M 10-Q · filed 2017-08-10 | $59.10M derived: sum of 3 quarters · filed 2017-08-10 | $98.30M derived: sum of 4 quarters · filed 2017-08-10 | ||||
| 2017-04-01 | $53.80M 10-Q · filed 2017-05-30 | -$96.00M derived: sum of 2 quarters · filed 2017-05-30 | -$56.80M derived: sum of 3 quarters · filed 2017-05-30 | -$163.30M derived: sum of 4 quarters · filed 2017-05-30 | ||||
| 2016-12-31 | -$149.80M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-05-22 | -$110.60M derived: sum of 2 quarters · filed 2017-05-23 | -$217.10M derived: sum of 3 quarters · filed 2017-05-23 | -$64.50M 10-K · filed 2017-05-22 | ||||
| 2016-10-01 | $39.20M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | -$67.30M derived: sum of 2 quarters · filed 2017-05-23 | $85.30M 10-Q/A · filed 2017-05-23 | $85.50M 10-Q · filed 2016-11-10 | -$6.20M derived: sum of 4 quarters · filed 2017-05-23 | |||
| 2016-07-02 | -$106.50M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $46.10M 10-Q/A · filed 2017-05-22 | $46.90M 10-Q · filed 2016-08-10 | -$45.40M derived: sum of 3 quarters · filed 2017-05-22 | -$83.00M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2016-04-02 | $152.60M 10-Q/A · filed 2017-05-22 | $152.10M 10-Q · filed 2016-05-16 | $61.10M derived: sum of 2 quarters · filed 2017-05-22 | $23.50M derived: sum of 3 quarters · filed 2017-05-22 | $134.30M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2015-12-31 | -$91.50M derived: 10-K 6 month − 10-Q 3 month · filed 2017-05-22 | -$129.10M 10-K · filed 2017-05-22 | -$128.20M 10-KT · filed 2016-02-25 | -$18.30M derived: sum of 3 quarters · filed 2017-05-22 | -$46.40M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2015-09-26 | -$37.60M 10-Q · filed 2015-11-02 | $73.20M derived: sum of 2 quarters · filed 2017-05-22 | $45.10M derived: sum of 3 quarters · filed 2017-05-22 | -$23.70M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2015-06-27 | $110.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $82.70M derived: sum of 2 quarters · filed 2017-05-22 | $13.90M derived: sum of 3 quarters · filed 2017-05-22 | -$51.00M 10-K · filed 2017-05-22 | -$52.10M 10-K · filed 2015-08-13 | |||
| 2015-03-28 | -$28.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | -$96.90M derived: sum of 2 quarters · filed 2015-04-29 | -$161.80M 10-Q · filed 2015-04-29 | -$165.70M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-12-27 | -$68.80M derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | -$133.70M 10-Q · filed 2015-02-05 | -$137.60M derived: sum of 3 quarters · filed 2016-02-25 | -$125.70M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-09-27 | -$64.90M 8-K · filed 2014-11-20 | -$68.80M derived: sum of 2 quarters · filed 2016-02-25 | -$56.90M derived: sum of 3 quarters · filed 2016-02-25 | -$46.30M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-28 | -$3.90M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $8.00M derived: sum of 2 quarters · filed 2016-02-25 | $18.60M derived: sum of 3 quarters · filed 2016-02-25 | $49.30M 10-KT · filed 2016-02-25 | ||||
| 2014-03-29 | $11.90M 10-Q · filed 2014-05-07 | $22.50M derived: sum of 2 quarters · filed 2014-05-07 | $53.20M 10-Q · filed 2014-05-07 | |||||
| 2013-12-28 | $10.60M 10-Q · filed 2014-02-06 | $37.70M 10-Q · filed 2014-02-06 | ||||||
| 2013-09-28 | -$16.51M 10-Q · filed 2013-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |